A report on the protein engineering market suggests it will grow at a CAGR of 12.4 percent, primarily due to protein-based drugs and pharmaceutical company development.
List view / Grid view
Filter the results
Watch Data Scientist Patrick O’Sullivan of Janssen describe how they reduce the amount of time spent preparing data for their million data point systems.
The UK BioIndustry Association’s bioProcessUK conference saw two awards given to Sharon Grimster and Dr Sarah Goulding for their work in the bioprocessing sector.
Research has revealed that the biotechnology industry was worth £1.3 billion in 2019, marking its third-highest year for investment.
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
A study has revealed that in 2018, almost half of the spending on brand medicines went to the supply chain and other entities in the US.
The mAb tislelizumab has been granted approval from Chinese authorities, making Boehringer Ingelheim Biopharmaceuticals the first MAH under the new system.
Epidyolex, which contains cannabidiol, can now be prescribed by doctors to epilepsy patients in the UK through the NHS.
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
Mergers and acquisitions in any market can define the landscape for its players. In this article, Emma Danks of Taylor Wessing reflects on recent M&A activity in the biopharmaceutical industry, highlighting influencing trends and what this might mean for the future.
The first gene therapy products are appearing commercially and the field is growing rapidly with over 350 clinical trials taking place in H1 of 2019 alone. So why is this area attracting so much attention? Dr Philip Probert and Dr Stuart Jamieson discuss the potential of gene therapy and the…
Application note: Non-targeted host cell protein monitoring in downstream process samples using micro Pillar Array Columns combined with mass spectrometry (μPACTM-MS)
This whitepaper reports on the use of μPAC™ in combination with MS for the characterisation of HCPs and their monitoring during downstream processing.
Pharmaceutical and biotechnology manufacturers must ensure the quality of materials – from incoming raw material through finished product.